KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
4/29/2019
4/29/2018
4/29/2017
4/29/2016
12/30/2015
Total Revenue
15,778
16,127
8,394
1,504
2,133
29
Cost of Revenue
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
Operating Expenses
Research Development
36,351
35,021
18,237
12,666
14,661
16,199
Selling General and Administrative
11,802
10,926
8,862
11,177
2,653
4,866
Total Operating Expenses
48,153
45,947
27,099
23,843
17,314
21,065
Operating Income or Loss
-32,375
-29,820
-18,705
-22,339
-15,181
-21,036
Interest Expense
-
-
-
-
-
1,188
Total Other Income/Expenses Net
7,477
7,731
2,818
3,700
3,695
-2,627
Income Before Tax
-23,000
-20,692
-15,805
-18,603
-11,436
-24,846
Income Tax Expense
-
124
-
-
-
-
Income from Continuing Operations
-23,124
-20,816
-15,805
-18,603
-11,436
-24,846
Net Income
-23,124
-20,816
-15,805
-18,603
-11,436
-24,846
Net Income available to common shareholders
-23,124
-20,816
-15,805
-20,775
-15,475
-24,846
Reported EPS
Basic
-
-1.38
-1.53
-4.47
-26.17
-18.20
Diluted
-
-1.38
-1.53
-4.47
-26.17
-18.20
Weighted average shares outstanding
Basic
-
15,081
10,322
4,647
591
1,363
Diluted
-
15,081
10,322
4,647
591
1,363
EBITDA
-
-29,442
-18,525
-22,299
-15,148
-23,525